Status:
COMPLETED
Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously
Lead Sponsor:
Pfizer
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The hypothesis of this study is that subcutaneous administration of tanezumab results in lower drug exposure compared to intravenous administration of tanezumab.
Eligibility Criteria
Inclusion
- Generally healthy
- BMI of 18-30 kg/m2
- more than 50 kg bodyweight.
Exclusion
- Pregnant
- exposure to biologic type drugs within the last 3 months
- history of allergic or anaphylactic reaction to a biologic drug
- use of tobacco- or nicotine containing products that is more than what is in 5 cigarettes per day
- excessive alcohol use.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT00788294
Start Date
November 1 2008
End Date
June 1 2009
Last Update
October 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Cypress, California, United States, 90630